Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 230Breast Neoplasms 187Ovarian Neoplasms 113Neoplasms 100Neoplasm Metastasis 59Lung Neoplasms 54Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 44Stomach Neoplasms 41Parkinson Disease 4, Autosomal Dominant Lewy Body 41Endometrial Neoplasms 37Carcinoma, Ovarian Epithelial 32Squamous Cell Carcinoma of Head and Neck 28Uterine Cervical Neoplasms 24Esophageal Neoplasms 21Carcinoma 21Colorectal Neoplasms 20Recurrence 19Melanoma 18Esophageal Squamous Cell Carcinoma 18Small Cell Lung Carcinoma 16Pancreatic Neoplasms 16Head and Neck Neoplasms 14Solid Tumors 12Adenocarcinoma 12Advanced Solid Tumors 11Carcinoma, Renal Cell 10Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8Solid Tumor 8

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Cancer × Paclitaxel × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡